WednesdayDec 13, 2017 11:43 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Granted U.S. Patent Regarding DehydraTECH™ Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office ("USPTO") increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs"), and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be…

Continue Reading

TuesdayDec 12, 2017 9:29 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Inks LOI to Acquire Outstanding Shares of Harvest Medicine Inc.

Abcann Global (TSX.V: ABCN) (OTCQB: ABCCF) this morning said that the company recently entered into a binding Letter of Intent (“LOI”) dated December 11, 2017 to acquire all outstanding securities of Canada’s fastest growing medical cannabis clinic, Harvest Medicine Inc. Per the terms of the agreement, Abcann will make a $1,500,000 cash payment and issue 1,056,338 common shares in the capital of ABcann valued at $1,500,000, based on a deemed price of $1.42 per share. Upon the closing of the transaction, Harvest Medicine founder and CEO, Shekhar Parmar, is anticipated to join ABcann’s executive team as Chief Strategy Officer and…

Continue Reading

FridayDec 08, 2017 8:31 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Retains Medical Director to Advise Cannabis Research Programs

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning reported that the company has hired Dr. M. Scott Alexander as a medical director. Alexander’s role will be to confirm the medical integrity of cannabis research programs conducted by the company’s subsidiary, Cannevert Therapeutics Ltd. In addition, Alexander will develop a medical affairs strategy to support cannabis strains currently in development. “Dr. Alexander brings a wealth of medical knowledge, a clear understanding of current clinical practice and regulatory needs, and a pledge to educate all stakeholders about therapeutic strains that are based on Cannevert’s experimental evidence,” Veritas CEO Dr. Lui…

Continue Reading

TuesdayDec 05, 2017 8:29 am

CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Cannevert Subsidiary Inks Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. Per the agreement, the Institute for Medical Cannabis will provide CTL with particular cannabis strains for upcoming human studies in the US territory. “We are pleased that Cannevert has identified a reputable producer that is focused on providing certified quality products, educating the medical community on the potential benefits of cannabis, and conducting clinical research on its products. They will…

Continue Reading

MondayDec 04, 2017 9:04 am

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Provides 2018 Strategy Update Regarding Growth Plans

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018. The company’s incoming president and CEO Nick Dean intends to focus on meeting the expected surge in demand in the recreational cannabis sector through strategic partnerships and by increasing Emblem’s total production capacity. Dean also intends to ramp up patient acquisition in the medical cannabis market utilizing the company’s strengths and quality products. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic…

Continue Reading

FridayDec 01, 2017 11:41 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Posts Q3 Results, Operational Update

Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently released financial results for the three and nine months ended September 30, 2017. Among other highlights from the third quarter, the company reported $43.4 million in cash, cash equivalents and marketable securities which provides a strong position for expansion plans for its high-tech Vanluven facility. Abcann also reported revenues of $614,000 for the nine months ended September 30, 2017, a considerable increase compared to $211,00 during the same period in 2016. Additionally, the company provided an update on operations, including the company’s strategy moving forward. “ABcann’s vision is to create a successful…

Continue Reading

FridayDec 01, 2017 10:46 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Stock, Option and Warrant Transactions

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced various stock, option and warrant transactions. The news release states, “Following issuance of these common shares, Lexaria will have 69,674,919 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.” No shares were sold or registered in the United States. In addition, John Docherty, President of Lexaria Bioscience Corp., recently issued a clip discussing the company's technology…

Continue Reading

TuesdayNov 28, 2017 9:33 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Research Arm’s Patent Filing for Use of Specific Cannabis Strain Acknowledged by US Patent Office

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), received an acknowledgement letter with the filing number of US 62/558,021 from the US Patent and Trademark Office (“USPTO”) for the filing it made in September for use of a specific cannabis strain to enhance the actions of opioid analgesics.  Veritas CEO, Dr. Lui Franciosi commented, “We are pleased with Cannevert’s latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for…

Continue Reading

MondayNov 27, 2017 9:15 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Present at LD Micro Main Event; Reports Warrant Exercise

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it will be presenting at the upcoming 10th annual LD Micro Main Event taking place December 5-7 in Los Angeles, California. Additionally, the company is filing its annual Form 10K which includes financial statements that will be available today at the Securities and Exchange Commission's website (www.sec.gov). Lexaria also said that through the exercise of warrants and a compensation option certificate previously granted, the company has received US $118,913. The compensation option certificate was exercised at…

Continue Reading

WednesdayNov 22, 2017 9:28 am

CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) CTL Subsidiary Inks Letter of Intent with FDI of Puerto Rico to Initiate Human Trials of CTL-X

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) recently announced that its 80% owned subsidiary, Cannevert Therapeutics Ltd. ("CTL"), signed a letter of intent with the Fundación de Investigación (“FDI”) in San Juan, Puerto Rico, to conduct the first human study of CTL-X for the treatment of pain. The study of CTL-X, CTL’s lead cannabis strain for pain, will be conducted in two stages to assess the treatment’s analgesic effects. “We are pleased to see Cannevert’s lead strain for pain is finally heading into human trials. It’s important to us to move quickly into this next phase of providing clinical…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977